Effect of Kuvan on Neurocognitive Function, Blood Phenylalanine Level, Safety, and Pharmacokinetics in Children With PKU
Status:
Completed
Trial end date:
2018-09-14
Target enrollment:
Participant gender:
Summary
This multicenter, open label study is designed to evaluate the safety of Kuvan® and its
effect on neurocognitive function, blood Phe concentration, and growth in children with PKU
who are 0-6 years old.